NO20060813L - Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav - Google Patents

Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav

Info

Publication number
NO20060813L
NO20060813L NO20060813A NO20060813A NO20060813L NO 20060813 L NO20060813 L NO 20060813L NO 20060813 A NO20060813 A NO 20060813A NO 20060813 A NO20060813 A NO 20060813A NO 20060813 L NO20060813 L NO 20060813L
Authority
NO
Norway
Prior art keywords
neu
hher2
gene encoding
optimized
codon
Prior art date
Application number
NO20060813A
Other languages
English (en)
Norwegian (no)
Inventor
Pasquale Gallo
Paolo Monaci
Maurizio Nuzzo
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of NO20060813L publication Critical patent/NO20060813L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20060813A 2003-07-21 2006-02-20 Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav NO20060813L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48923703P 2003-07-21 2003-07-21
PCT/EP2004/008234 WO2005012527A1 (en) 2003-07-21 2004-07-20 Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof

Publications (1)

Publication Number Publication Date
NO20060813L true NO20060813L (no) 2006-03-20

Family

ID=34115329

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060813A NO20060813L (no) 2003-07-21 2006-02-20 Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav

Country Status (14)

Country Link
US (2) US20070111957A1 (de)
EP (1) EP1649020B1 (de)
JP (1) JP4772674B2 (de)
KR (1) KR101141507B1 (de)
CN (2) CN100558894C (de)
AU (1) AU2004261724B2 (de)
CA (1) CA2532460C (de)
IL (1) IL173208A (de)
IS (1) IS8200A (de)
NO (1) NO20060813L (de)
NZ (1) NZ544543A (de)
RU (1) RU2397249C2 (de)
WO (1) WO2005012527A1 (de)
ZA (1) ZA200600248B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061462B1 (de) 2007-07-02 2019-02-27 Etubics Corporation Verfahren und zusammensetzungen zur erzeugung eines adenovirusvektors zur verwendung mit mehreren impfungen
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
CN103555765B (zh) * 2013-05-30 2015-01-07 中南大学湘雅医院 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用
MX2016013149A (es) * 2014-04-10 2017-04-27 Seattle Children's Hospital (Dba Seattle Children's Res Institute) Produccion de celulas t modificadas, mediante transposon bella durmiente, acoplada con seleccion por metotrexato.
US11352642B2 (en) 2015-01-09 2022-06-07 Etubics Corporation Methods and compositions for combination immunotherapy
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
CA2994829A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
JP7171433B2 (ja) 2015-10-30 2022-11-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
CA3073310A1 (en) * 2017-08-24 2019-02-28 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody
CN112941132B (zh) * 2021-05-17 2021-07-23 烟台市华昕生物医药科技有限公司 一种利用大肠杆菌表达寡肽-1的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
WO1995030331A1 (en) * 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
IT1276662B1 (it) * 1995-04-04 1997-11-03 Uni Degli Studi Camerino Vaccini polinucleotidici
WO2000044899A1 (en) * 1999-01-29 2000-08-03 Corixa Corporation Her-2/neu fusion proteins
EP1366153A2 (de) * 2000-08-14 2003-12-03 Corixa Corporation Verbindungen und methoden für die therapie und diagnose von her-2/neu-assoziierten malignomen
AU9456201A (en) 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CN1164330C (zh) * 2001-07-19 2004-09-01 中国医学科学院基础医学研究所 一种重组复制缺陷型腺病毒载体狂犬病毒基因工程疫苗
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
AU2003286770A1 (en) * 2002-10-30 2004-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS
JP2006525787A (ja) 2003-01-03 2006-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー アカゲザルＨＥＲ２／ｎｅｕ、これをコードするヌクレオチド及びその使用

Also Published As

Publication number Publication date
IL173208A0 (en) 2006-06-11
JP4772674B2 (ja) 2011-09-14
NZ544543A (en) 2009-03-31
RU2397249C2 (ru) 2010-08-20
JP2006527989A (ja) 2006-12-14
ZA200600248B (en) 2007-03-28
RU2006105195A (ru) 2006-06-27
CN100558894C (zh) 2009-11-11
KR20060052852A (ko) 2006-05-19
AU2004261724B2 (en) 2010-06-17
CA2532460C (en) 2012-04-24
EP1649020A1 (de) 2006-04-26
IL173208A (en) 2014-06-30
CA2532460A1 (en) 2005-02-10
US7662586B2 (en) 2010-02-16
WO2005012527A1 (en) 2005-02-10
KR101141507B1 (ko) 2012-05-08
WO2005012527A9 (en) 2006-03-02
AU2004261724A1 (en) 2005-02-10
US20090098604A1 (en) 2009-04-16
CN1826409A (zh) 2006-08-30
US20070111957A1 (en) 2007-05-17
EP1649020B1 (de) 2017-01-11
CN101173282A (zh) 2008-05-07
IS8200A (is) 2005-12-27
CN101173282B (zh) 2011-04-06

Similar Documents

Publication Publication Date Title
NO20060813L (no) Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav
NO20055708L (no) Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav
Singh et al. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse
EP1716173B8 (de) Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
Liu et al. Telomerase in cancer immunotherapy
WO2019002444A9 (en) NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME
ATE474048T1 (de) Her2/neu fusionsproteine
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
IL198012A0 (en) Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
ATE472339T1 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
Wiedermann et al. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
Hernández-Ramírez et al. Expression in algae of a chimeric protein carrying several epitopes from tumor associated antigens
Kwak et al. Vaccine strategy in melanoma
Hage et al. TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor‐specific cytotoxic T lymphocytes
Nelson et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the ‘self’tumor-associated antigen, neu in a rat mammary tumor model
Park et al. Effective immunotherapy of cancer by DNA vaccination
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
EP1536006A4 (de) Krebsantigene und deren nutzung
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
HUP0204216A2 (en) A new use of antibodies as vaccines
Biragyn et al. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
Luo et al. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MSD ITALIA SRL, IT

FC2A Withdrawal, rejection or dismissal of laid open patent application